The FDA has accepted for review Sanofi's marketing application for the use of its monoclonal antibody therapy isatuximab as a treatment for patients with relapsed/refractory multiple myeloma. The agency set the action date for April 30, 2020.
Sanofi's application for myeloma drug isatuximab accepted by FDA
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.